NASDAQ: RAPP
Rapport Therapeutics Inc Stock Ownership - Who owns Rapport Therapeutics?

Insider buying vs selling

Have Rapport Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Third Rock Ventures V LPDirector2026-10-301,190,476$21.00
$25.00MBuy
Third Rock Ventures V LPDirector2026-10-30238,095$21.00
$5.00MBuy
James HealyDirector2026-10-28952,380$21.00
$20.00MBuy
James HealyDirector2026-10-283,772$21.00
$79.21kBuy
James HealyDirector2026-10-286,933$21.00
$145.59kBuy
James HealyDirector2026-10-286,395$21.00
$134.30kBuy
Ramiro SanchezDirector2026-10-233,600$27.36
$98.48kBuy
John MaraganoreDirector2026-10-221,172$26.92
$31.55kBuy
Wendy B. YoungDirector2026-10-223,789$26.39
$99.99kBuy
Paul M. SilvaDirector2026-10-223,680$27.08
$99.64kBuy

1 of 9

RAPP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RAPP insiders and whales buy or sell their stock.

RAPP Shareholders

What type of owners hold Rapport Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Third Rock Ventures V LP16.27%9,647,532$223.44MInsider
James Healy8.21%4,869,482$112.78MInsider
Arch Venture Partners XII LLC6.29%3,728,738$86.36MInsider
Abraham Ceesay1.10%654,951$15.17MInsider
Steven M. Paul1.01%596,688$13.82MInsider
David Bredt0.66%393,075$9.10MInsider
Bradley S. Galer0.33%197,426$4.57MInsider
Krishnaswamy Yeleswaram0.33%195,862$4.54MInsider
Cheryl Gault0.24%139,914$3.24MInsider
Reid M. Huber0.03%20,400$472.46kInsider

1 of 3

RAPP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RAPP0.08%34.56%Net BuyingNet Buying
IMCR0.10%4.25%Net Selling
ANAB0.07%99.93%Net BuyingNet Buying
QURE0.09%9.91%Net SellingNet Selling
URGN0.08%20.35%Net SellingNet Selling

Rapport Therapeutics Stock Ownership FAQ

Who owns Rapport Therapeutics?

Rapport Therapeutics (NASDAQ: RAPP) is owned by 0.08% institutional shareholders, 34.56% Rapport Therapeutics insiders, and 65.35% retail investors. Third Rock Ventures V LP is the largest individual Rapport Therapeutics shareholder, owning 9.65M shares representing 16.27% of the company. Third Rock Ventures V LP's Rapport Therapeutics shares are currently valued at $223.44M.

If you're new to stock investing, here's how to buy Rapport Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.